Literature DB >> 29159745

Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection.

Stefanie Bette1, Melanie Barz2, Benedikt Wiestler1, Thomas Huber3, Julia Gerhardt2, Niels Buchmann2, Stephanie E Combs4,5,6, Friederike Schmidt-Graf7, Claire Delbridge8, Claus Zimmer1, Jan S Kirschke1, Bernhard Meyer2, Yu-Mi Ryang2, Florian Ringel2, Jens Gempt9.   

Abstract

BACKGROUND: Incomplete resection of glioblastoma is discussed controversially in the era of combined radiochemotherapy.
OBJECTIVE: The aim of this study was to analyze the benefit of subtotal tumor resection for glioblastoma patients as this was recently questioned in the era of radiochemotherapy.
METHODS: Overall, 209 patients undergoing surgery for newly diagnosed WHO grade IV gliomas were retrospectively analyzed, and pre- and postoperative tumor volumes were manually segmented (cm3). Survival analyses were performed, including prognostic factors such as age, Karnofsky performance score (KPS), O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, and adjuvant treatment regimen.
RESULTS: Pre- and postoperative tumor volume is significantly associated with pre- and postoperative KPS, as well as age (p < 0.001). Postoperative tumor volume remained a significant prognostic factor in a multivariate analysis, independent of other prognostic factors (hazard ratio 1.0365, 95% confidence interval 1.0235-1.0497, p < 0.001).
CONCLUSIONS: In the era of molecularly-driven radiochemotherapy, glioblastoma surgery remains a major prognostic factor. Even in situations in which a gross total resection cannot be achieved, maximum safe reduction of tumor burden should be attempted.

Entities:  

Mesh:

Year:  2017        PMID: 29159745     DOI: 10.1245/s10434-017-6253-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  A mesoscopic simulator to uncover heterogeneity and evolutionary dynamics in tumors.

Authors:  Juan Jiménez-Sánchez; Álvaro Martínez-Rubio; Anton Popov; Julián Pérez-Beteta; Youness Azimzade; David Molina-García; Juan Belmonte-Beitia; Gabriel F Calvo; Víctor M Pérez-García
Journal:  PLoS Comput Biol       Date:  2021-02-10       Impact factor: 4.475

2.  Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.

Authors:  Akifumi Hagiwara; Talia C Oughourlian; Nicholas S Cho; Jacob Schlossman; Chencai Wang; Jingwen Yao; Catalina Raymond; Richard Everson; Kunal Patel; Sergey Mareninov; Fausto J Rodriguez; Noriko Salamon; Whitney B Pope; Phioanh L Nghiemphu; Linda M Liau; Robert M Prins; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2022-06-01       Impact factor: 13.029

3.  Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.

Authors:  Jieqiong Wen; Wanbin Chen; Yayun Zhu; Pengbo Zhang
Journal:  BMC Cancer       Date:  2021-01-19       Impact factor: 4.430

Review 4.  Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas.

Authors:  Maximilian Scheer; Sandra Leisz; Eberhard Sorge; Olha Storozhuk; Julian Prell; Ivy Ho; Anja Harder
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

5.  Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale - a bicentric retrospective study.

Authors:  Melanie Barz; Julia Gerhardt; Stefanie Bette; A Kaywan Aftahy; Thomas Huber; Stephanie E Combs; Yu-Mi Ryang; Benedikt Wiestler; Marco Skardelly; Irina Gepfner-Tuma; Felix Behling; Friederike Schmidt-Graf; Bernhard Meyer; Jens Gempt
Journal:  BMC Neurol       Date:  2021-11-15       Impact factor: 2.474

6.  Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.

Authors:  Hui K Gan; Sagun Parakh; Andrew B Lassman; Aidan Seow; Eddie Lau; Sze Ting Lee; Malaka Ameratunga; Yuliya Perchyonok; Diana Cao; Ingrid J G Burvenich; Graeme J O'Keefe; Angela Rigopoulos; Erica Gomez; David Maag; Andrew M Scott
Journal:  Neurooncol Adv       Date:  2021-08-03

7.  Aggressiveness of Grade 4 Gliomas of Adults.

Authors:  Mariana Deacu; Any Docu Axelerad; Steliana Popescu; Theodor Sebastian Topliceanu; Mariana Aschie; Madalina Bosoteanu; Georgeta Camelia Cozaru; Ana Maria Cretu; Raluca Ioana Voda; Cristian Ionut Orasanu
Journal:  Clin Pract       Date:  2022-09-03

8.  A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma.

Authors:  Christoph Straube; Kerstin A Kessel; Stefanie Antoni; Jens Gempt; Bernhard Meyer; Juergen Schlegel; Friederike Schmidt-Graf; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2020-05-06       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.